Business Context and Reporting Period
This Form 8-K, dated February 11, 2019, reports that ADMA Biologics, Inc. entered into a new senior secured term loan facility and terminated its prior credit agreement. The filing also provides a regulatory update regarding the Company's lead product, BIVIGAM.
Key Financial Metrics and Debt Structure
- New Credit Facility: Total principal amount up to $72.5 million, consisting of an initial $45.0 million term loan and a potential additional $27.5 million term loan.
- Use of Proceeds: $30.0 million used to pay off the existing Marathon Healthcare Finance Fund facility; $2.8 million for deferred fees; $6.5 million for prepayment penalties; $0.7 million for accrued interest; remainder for transaction fees and expenses.
- Interest Rate: 7.5% plus the greater of one-month LIBOR or 3.5%. Increases by 400 basis points upon an Event of Default.
- Maturity: March 1, 2022. No scheduled principal payments prior to maturity.
- Equity Issuance: Issued a warrant to purchase 1,360,000 shares of common stock at an exercise price of $3.28 (subject to adjustment), expiring February 11, 2029.
- Liquidity Covenants: Must maintain a minimum cash balance of $3.0 million.
- Revenue Covenants: Must meet specific trailing 12-month revenue thresholds ranging from $6.2 million (Q3 2019) to $55.0 million (Q4 2021).
Material Changes Versus Prior Period
The Company terminated its previous credit agreement with Marathon Healthcare Finance Fund, L.P., dated October 10, 2017. This transaction replaced the prior debt structure with a new facility from Perceptive Credit Holdings II, LP, secured by a first-priority lien on substantially all tangible and intangible assets, including intellectual property.
Outlook, Risks, and Regulatory Status
- Regulatory Update (BIVIGAM): The Company received a Complete Response Letter (CRL) from the FDA on December 19, 2018, regarding a Prior Approval Supplement (PAS). Responses were submitted on January 7, 2019. The FDA is actively reviewing the resubmission, but the Company cannot predict the timing of authorization.
- Conditions for Additional Funding: The additional $27.5 million term loan is contingent upon FDA approval of the BIVIGAM PAS or approval of the commercialization of product candidate RI-002, and must be drawn by June 30, 2020.
- Risks: Events of Default include non-payment, covenant violations, and regulatory events. Default triggers an interest rate increase and potential acceleration of the entire loan balance.
- Prepayment Penalties: Significant prepayment premiums apply (5.0% in year 1, 4.0% in year 2, 3.0% in year 3).
Investor Verification Checklist
- Verify the status of the FDA review for the BIVIGAM PAS resubmission, as the additional $27.5 million loan tranche depends on this approval.
- Confirm the Company's ability to meet the escalating revenue covenants ($6.2M to $55.0M) to avoid default.
- Review the impact of the warrant issuance (1.36M shares) on potential future dilution.
- Assess the liquidity position against the $3.0 million minimum cash balance covenant.
- Examine the full text of the Credit Agreement (Exhibit 10.1) for specific definitions of "Material Adverse Changes" and other restrictive covenants.